Palatin Technologies plans to move two obesity-targeting drugs — experimental therapies designed to activate the melanocortin-4 receptor (MC4R) protein, which is involved in appetite and energy balance — into clinical testing in people with Prader-Willi syndrome (PWS) this year. Planned trials will also test the company’s candidates in…